Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.
A business making money today isn’t necessarily a winner, which is why we analyze companies across multiple dimensions at StockStory. Keeping that in mind, here is one profitable company that balances growth and profitability and two that may face some trouble.
Two Stocks to Sell:
AT&T (T)
Trailing 12-Month GAAP Operating Margin: 19.8%
Founded by Alexander Graham Bell, AT&T (NYSE: T) is a multinational telecomm conglomerate providing a range of communications and internet services.
Why Are We Out on T?
- Annual revenue declines of 1.3% over the last five years indicate problems with its market positioning
- Performance over the past five years shows each sale was less profitable as its earnings per share dropped by 7.5% annually, worse than its revenue
- Free cash flow margin is expected to remain in place over the coming year
At $21.04 per share, AT&T trades at 9x forward P/E. Dive into our free research report to see why there are better opportunities than T.
Payoneer (PAYO)
Trailing 12-Month GAAP Operating Margin: 11.7%
Founded during the early days of global e-commerce in 2005 to solve international payment challenges, Payoneer (NASDAQ: PAYO) provides financial technology services that enable small and medium-sized businesses to send and receive payments globally across borders.
Why Are We Hesitant About PAYO?
- Annual earnings per share growth of 4.8% underperformed its revenue over the last two years, showing its incremental sales were less profitable
- ROE of 7.3% reflects management’s challenges in identifying attractive investment opportunities
Payoneer is trading at $7.07 per share, or 25x forward P/E. Read our free research report to see why you should think twice about including PAYO in your portfolio.
One Stock to Watch:
Astrana Health (ASTH)
Trailing 12-Month GAAP Operating Margin: 2.5%
Formerly known as Apollo Medical Holdings until early 2024, Astrana Health (NASDAQ: ASTH) operates a technology-powered healthcare platform that enables physicians to deliver coordinated care while successfully participating in value-based payment models.
Why Are We Fans of ASTH?
- Impressive 55.7% annual revenue growth over the last two years indicates it’s winning market share this cycle
- Forecasted revenue growth of 16.5% for the next 12 months indicates its momentum over the last two years is sustainable
- Earnings per share have massively outperformed its peers over the last five years, increasing by 13.2% annually
Astrana Health’s stock price of $48.02 implies a valuation ratio of 15.3x forward P/E. Is now a good time to buy? See for yourself in our full research report, it’s free.
Stocks We Like Even More
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
